Joseph Frattaroli
2022
In 2022, Joseph Frattaroli earned a total compensation of $574.8K as Chief Financial Officer at Inhibikase Therapeutics, a 18% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $136,000 |
|---|---|
| Option Awards | $42,932 |
| Salary | $395,833 |
| Total | $574,765 |
Frattaroli received $395.8K in salary, accounting for 69% of the total pay in 2022.
Frattaroli also received $136K in non-equity incentive plan and $42.9K in option awards.
Rankings
In 2022, Joseph Frattaroli's compensation ranked 4,121st out of 5,725 executives tracked by ExecPay. In other words, Frattaroli earned more than 28.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,121 out of 5,725 | 28th |
Division Manufacturing | 2,325 out of 3,111 | 25th |
Major group Chemicals And Allied Products | 1,125 out of 1,410 | 20th |
Industry group Drugs | 1,055 out of 1,311 | 20th |
Industry Biological Products, Except Diagnostic Substances | 249 out of 291 | 14th |
Source: SEC filing on May 5, 2023.
Frattaroli's colleagues
We found one more compensation record of an executive who worked with Joseph Frattaroli at Inhibikase Therapeutics in 2022.
2022
Milton Werner
Inhibikase Therapeutics